JP2022547906A - 細胞死を阻害する化合物 - Google Patents
細胞死を阻害する化合物 Download PDFInfo
- Publication number
- JP2022547906A JP2022547906A JP2022514837A JP2022514837A JP2022547906A JP 2022547906 A JP2022547906 A JP 2022547906A JP 2022514837 A JP2022514837 A JP 2022514837A JP 2022514837 A JP2022514837 A JP 2022514837A JP 2022547906 A JP2022547906 A JP 2022547906A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- primidone
- ripk1
- cell death
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000030833 cell death Effects 0.000 title claims abstract description 81
- 150000001875 compounds Chemical class 0.000 title abstract description 18
- 229960002393 primidone Drugs 0.000 claims abstract description 130
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims abstract description 128
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims abstract description 96
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims abstract description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 60
- 201000010099 disease Diseases 0.000 claims abstract description 48
- 230000001419 dependent effect Effects 0.000 claims abstract description 47
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 239000002207 metabolite Substances 0.000 claims abstract description 27
- 239000012453 solvate Substances 0.000 claims abstract description 25
- 230000001575 pathological effect Effects 0.000 claims abstract description 20
- 230000021597 necroptosis Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 206010063837 Reperfusion injury Diseases 0.000 claims description 19
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 16
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 13
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 10
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 6
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 101100034357 Arabidopsis thaliana RIPK gene Proteins 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000033626 Renal failure acute Diseases 0.000 claims description 5
- 201000011040 acute kidney failure Diseases 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 3
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 108091007065 BIRCs Proteins 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 claims description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000033464 Reiter syndrome Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 206010053879 Sepsis syndrome Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 231100000836 acute liver failure Toxicity 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 claims description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 208000002574 reactive arthritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 28
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 26
- WIKGAEMMNQTUGL-UHFFFAOYSA-N 5-[(7-chloro-1h-indol-3-yl)methyl]-3-methylimidazolidine-2,4-dione Chemical compound O=C1N(C)C(=O)NC1CC1=CNC2=C(Cl)C=CC=C12 WIKGAEMMNQTUGL-UHFFFAOYSA-N 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 241001678559 COVID-19 virus Species 0.000 description 20
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 18
- 230000001404 mediated effect Effects 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- -1 alkaline earth metal salts Chemical class 0.000 description 17
- 230000006907 apoptotic process Effects 0.000 description 13
- 208000025721 COVID-19 Diseases 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- JFZHPFOXAAIUMB-UHFFFAOYSA-N Phenylethylmalonamide Chemical compound CCC(C(N)=O)(C(N)=O)C1=CC=CC=C1 JFZHPFOXAAIUMB-UHFFFAOYSA-N 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 10
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 206010013975 Dyspnoeas Diseases 0.000 description 9
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 208000000059 Dyspnea Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 229960002695 phenobarbital Drugs 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 206010013911 Dysgeusia Diseases 0.000 description 6
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 6
- 101710083978 Mixed lineage kinase domain-like protein Proteins 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 235000019564 dysgeusia Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 229940126062 Compound A Drugs 0.000 description 4
- 206010011376 Crepitations Diseases 0.000 description 4
- 239000003154 D dimer Substances 0.000 description 4
- 102000009058 Death Domain Receptors Human genes 0.000 description 4
- 108010049207 Death Domain Receptors Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108050000784 Ferritin Proteins 0.000 description 4
- 102000008857 Ferritin Human genes 0.000 description 4
- 238000008416 Ferritin Methods 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 4
- 208000037656 Respiratory Sounds Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 108010052295 fibrin fragment D Proteins 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001686 pro-survival effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000000153 supplemental effect Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010025327 Lymphopenia Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010038687 Respiratory distress Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000011976 chest X-ray Methods 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000000021 kinase assay Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 231100001023 lymphopenia Toxicity 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000036387 respiratory rate Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- NEQZWEXWOFPKOT-BYRRXHGESA-N 5Z-7-oxozeaenol Chemical compound O([C@@H](C)C\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(OC)=CC=2O NEQZWEXWOFPKOT-BYRRXHGESA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102000004091 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 2
- 108700011067 Necrosome Proteins 0.000 description 2
- 101150071716 PCSK1 gene Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010063897 Renal ischaemia Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Chemical class 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000003271 compound fluorescence assay Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 208000036696 Microcytic anaemia Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 101710092490 Protein kinase 3 Proteins 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000037892 acute myocardial injury Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000008777 canonical pathway Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- NEQZWEXWOFPKOT-UHFFFAOYSA-N f152A1 Natural products C1=CCC(O)C(O)C(=O)C=CCC(C)OC(=O)C=2C1=CC(OC)=CC=2O NEQZWEXWOFPKOT-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000013795 induction of necroptosis Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940090010 mysoline Drugs 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000007755 survival signaling Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
Description
制御されたネクローシスの形態であるネクロトーシスは、カスパーゼ非依存性のプログラム細胞死機構である。ネクロトーシスは、受容体共役タンパク質キナーゼ3(RIPK3)活性化およびそれに従う偽キナーゼ基質混合系統キナーゼドメイン様タンパク質(MLKL)のRIPK3媒介リン酸化によって媒介される(Choら、2009;Sunら、2012)。この初期刺激は、MLKLオリゴマー化、原形質膜移行、および脂質二重層の致死的透過をもたらす立体配座変化を促し、細胞内容物の放出をもたらし、これが炎症反応を引き起こす。
ネクロトーシスの活性化は、両方ともネクロトーシスの重要な下流メディエーターである2つのタンパク質、RIPK3およびMLKLの活性化を媒介するタンパク質である、受容体共役タンパク質1(RIPK1)の活性を必要とすることが知られている。RIPK1阻害剤は、ネクロトーシス経路でのその中心的機能のために、多くの疾患で起こる病理学的レベルの細胞死を予防するのに適した有用な治療薬として提案されている。
69歳の男性は、最高39℃の発熱および進行性の倦怠感のために、かかりつけ医からの紹介後に本クリニックに来院した。症状は、来院の10日前に発熱感および乾性咳で始まっていた。さらに、患者は味覚異常および寝汗があるが、息切れはないと報告した。患者は到着時にSARS-CoV-2感染について陽性を示し、この研究のための試料が1日後に採取された。患者の唯一の既往症は動脈性高血圧症であった。呼吸数は毎分20回、心拍数は毎分70拍、血圧は130/80mmHg、体温は38.3℃であった。血中酸素飽和度は、周囲空気下で96%であった。身体検査では、両肺の底部でのファインクラックルが明らかにされたが、それ以外は取り立てるほどではなかった。胸部X線で左肺の底部に小さな浸潤物が見られた。検査結果は、リンパ球減少症および炎症マーカー(C反応性タンパク質、IL-6、フェリチンおよびD-ダイマー)の増加を示した。アセトアミノフェンによる対症療法を開始した。治療の経過中、症状は徐々に減少したが、味覚異常は続いた。2週間の治療およびSARS-CoV-2について陰性を示した後、患者を帰宅させた。
49歳の男性が別の病院から本クリニックに転院された。患者は、最高40℃の熱、進行性の咳、および4日続いた鼻汁を報告した。患者は、入院の1日前に他の病院でSARS-CoV-2感染について陽性を示し、本病院の入院時に再検査は境界陽性を示した。翌日、この研究のための試料を採取した。患者の既存の病状は、II型糖尿病に限定された。来院時、患者は、毎分19の呼吸数で軽度の息切れを訴えたが、それ以外は健康に見えた。患者の血圧は145/80mmHg、患者の心拍数は毎分80拍、患者の体温は38.9℃であった。聴診により、両肺の底部でのファインクラックルが明らかになったが、それ以外の身体検査では、顕著なものはなかった。鼻カニューレを通した2l/分の酸素流の補充下で、血中酸素飽和度は93%であった。両肺の底部にある浸潤物が胸部X線で見られた。検査結果は、炎症マーカー(C反応性タンパク質、IL-6、フェリチンおよびD-ダイマー)の増加およびリンパ球減少が顕著であった。対症療法には、アセトアミノフェンおよびクリスタロイド溶液の静脈内適用が含まれた。入院の5日後、患者は、息切れの増加を報告した。動脈血液ガス分析は、鼻カニューレを通した3l/分の酸素流の補給下で、酸素分圧62mmHgの低酸素血症を示した。酸素の補給を非再呼吸式マスクに切り替え、酸素流を4l/分に増加した。その後、呼吸困難は5日間にわたって解消され、その時点で酸素の補給を中止した。患者の状態は、継続的な支持療法の下で改善した。2週間の治療およびSARS-CoV-2について陰性を示した後、患者を帰宅させた。
64歳の男性は、近くのキャンプ場で卒倒した後、本病院に入院した。救急救命士が低血糖と診断し(グルコース49mg/dl、基準範囲76~108mg/dl)、静脈内グルコース溶液を適用した後、患者は急速に意識を取り戻した。他の症状は認められず、特に味覚異常、咳、発熱または呼吸困難は認められなかった。呼吸数は毎分16回、血圧は142/76mmHg、心拍数は毎分78拍、体温は36.7℃であった。身体検査は、中等度の肥満以外は取り立てるほどのこともなく、放射線科検査同様、検査結果は感染または炎症の徴候を示さなかった。患者が病院に入院する際の慣例検査でSARS-CoV-2感染が検出され、患者は2日間隔離され続けた。既往症は、I型糖尿病および肥満に限定された。さらなる重篤な症状は発症せず、血糖値が安定したため、経過観察面会のためにかかりつけ医に行くよう提示をして、患者を最初の来院から72時間後に14日間自宅で隔離させた。
75歳の男性は、乾性咳および重度の呼吸困難を呈していた別の病院の緊急治療室で最初に評価された。症状は、2日の経過にわたって徐々に増加し、最高39℃の発熱が生じた。患者は、到着時にSARS-CoV-2感染について陽性を示した。既往症には、II型糖尿病、動脈性高血圧、喘息性肺疾患、甲状腺機能低下症および良性前立腺過形成が含まれた。身体検査は、患者が両肺の底部にわたるクラックルを伴う明らかな呼吸窮迫にあることを示した。呼吸数は毎分30回、血圧は110/65mmHg、心拍数は毎分96拍、温度は38.4℃であった。患者の状態が悪化し続けたため、成功した挿管後に人工呼吸器を装着した。その後、集中治療室の滞在が長引いた。6週間の治療後、患者は離脱し、抜管が成功したが、重度の咳が再発し、胸部のCTスキャンは、重感染のわずかな兆候もなくCOVID-19の放射線学的徴候を示した。反復試験ではSARS-CoV-2について継続して陽性を示し、この研究のための試料を取得した。高感度トロポニン試験は、新たに上昇したトロポニンlレベル12,400ng/l(基準範囲、45ng/l未満)を示し、急性心筋損傷を示した。EKGは病理学的徴候を示さなかった。ASS500mgおよびヘパリンによる治療を開始したが、入院時に侵襲的診断は実施されておらず、心筋梗塞も心筋炎も除外されていなかった。
41歳の女性は、関節痛、微熱および咳のために本病院に入院した。患者は最近、後にSARS-CoV-2感染について陽性を示した患者の姉妹に訪問された。非常に疲れを感じたこと以外、さらなる症状に気付かず、特に呼吸困難または味覚異常はなかった。唯一の既往症は、軽度のサラセミアであった。入院時の呼吸数は毎分16回、血圧は110/70mmHg、心拍数は毎分90拍、体温は37.7℃であった。身体検査は、中程度の肥満を除いて、取り立てるほどのことはなかった。検査結果は、軽度の小球性貧血、中程度のリンパ球減少症、ならびにC反応性タンパク質レベルの中程度の上昇を示した。胸部のX線は、感染症または炎症の徴候を示さなかった。患者を入院させ、この研究のための試料を取得したときに、SARS-CoV-2感染が検出された。患者は状態が安定したままであり、2日間の対症療法後、退院して自宅で自己隔離した。
32歳の男性は別の病院から転院された。患者は以前、東ヨーロッパで休暇を過ごし、ドイツへの帰国直後に重度の呼吸困難、最高39.5℃の発熱および味覚異常を発症した。患者は、他の病院でSARS-CoV-2感染について陽性を示し、そこでの身体検査は、患者が両肺の底部にわたるクラックルを伴う明らかな呼吸窮迫にあることを示した。呼吸数は毎分32回、血圧は124/74mmHg、心拍数は毎分98拍、温度は38.9℃であった。胸部のCTスキャンは、両肺の底部に顕著な浸潤物を示し、炎症の検査マーカー(C反応性タンパク質、IL-6、フェリチンおよびD-ダイマー)が著しく増加した。呼吸窮迫が増加したため、集中治療室に患者を移すことを決定し、そこでのSARS-CoV-2の反復試験が陽性であり、この研究のための試料を取得した。呼吸数は毎分40回に増加し、血中酸素飽和度は90%に低下したが、挿管が必要であるとはみなされず、患者は、持続的気道陽圧による換気およびデキサメタゾンによる治療下で改善した。
・ SARS-CoV-2陰性被検対照1(NC1):既往症のない43歳の男性。
・ SARS-CoV-2陰性被検対照2(NC2):既往症のない57歳の女性。
・ SARS-CoV-2陰性被検対照3(NC3):既往症のない41歳の男性。
・ SARS-CoV-2陰性被検対照4(NC4):既往症のない79歳の女性。
・ SARS-CoV-2陰性被験対照5(NC5):既往症のない29歳の男性。
・ SARS-CoV-2陰性被検対照6(NC6):既往症のない58歳の男性。
Cheng,Y.ら、Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury.J Clin Invest.101(9),1992-1999(1998)
Claims (15)
- 病理学的レベルのRIPK1依存性細胞死を伴う疾患を治療する方法で使用するための、プリミドンまたはその薬学的に許容される活性代謝産物、誘導体、塩もしくは溶媒和物。
- 前記疾患が、再灌流傷害疾患、全身性炎症性疾患、移植関連疾患、神経変性疾患、自己免疫疾患、眼科疾患、肺疾患、およびRIPK発現腫瘍疾患からなる群から選択される、請求項1に記載の方法で使用するためのプリミドンまたはその薬学的に許容される活性代謝産物、誘導体、塩もしくは溶媒和物。
- 前記再灌流傷害疾患が、心筋梗塞、脳卒中、急性腎不全および急性肝不全から選択される、請求項1に記載の方法で使用するためのプリミドンまたはその薬学的に許容される活性代謝産物、誘導体、塩もしくは溶媒和物。
- 前記神経変性疾患が、アルツハイマー病、パーキンソン病、ハンチントン病、および筋萎縮性側索硬化症(ALS)、外傷性脳損傷および多発性硬化症(MS)から選択される、請求項1に記載の方法で使用するためのプリミドンまたはその薬学的に許容される活性代謝産物、誘導体、塩もしくは溶媒和物。
- 前記自己免疫疾患が、潰瘍性大腸炎、クローン病、リウマチ性関節炎、自己免疫性心筋症、自己免疫性肝炎、紅斑性狼瘡、グレーブス病、ギラン・バレー症候群(GBS)、橋本甲状腺炎、特発性血小板減少性紫斑病、若年性特発性関節炎、重症筋無力症、尋常性天疱瘡、乾癬、ライター症候群、強皮症、シェーグレン症候群、血管炎、白斑およびヴェーゲナー肉芽腫症から選択される、請求項1に記載の方法で使用するためのプリミドンまたはその薬学的に許容される活性代謝産物、誘導体、塩もしくは溶媒和物。
- 前記全身性炎症性疾患が敗血症および全身性炎症反応症候群(SIRS)から選択されるか、または前記肺疾患が慢性閉塞性肺疾患(COPD)もしくは急性呼吸窮迫症候群(ARDS)、特にコロナウイルス誘発性ARDSである、請求項1に記載の方法で使用するためのプリミドンまたはその薬学的に許容される活性代謝産物、誘導体、塩もしくは溶媒和物。
- プリミドンまたはその薬学的に許容される活性代謝産物、誘導体、塩もしくは溶媒和物を含む、病理学的レベルのRIPK1依存性細胞死を伴う疾患または状態を治療する方法で使用するための医薬組成物。
- 前記疾患が、再灌流傷害疾患、全身性炎症性疾患、移植関連疾患、神経変性疾患、自己免疫疾患、眼科疾患、肺疾患、およびRIPK発現腫瘍疾患からなる群から選択される、請求項7に記載の方法で使用するための医薬組成物。
- 前記再灌流傷害疾患が、心筋梗塞、脳卒中、急性腎不全および急性肝不全から選択される、請求項7に記載の方法で使用するための医薬組成物。
- 前記神経変性疾患が、アルツハイマー病、パーキンソン病、ハンチントン病、および筋萎縮性側索硬化症(ALS)、外傷性脳損傷および多発性硬化症(MS)から選択される、請求項7に記載の方法で使用するための医薬組成物。
- 前記自己免疫疾患が、潰瘍性大腸炎、クローン病、リウマチ性関節炎、自己免疫性心筋症、自己免疫性肝炎、紅斑性狼瘡、グレーブス病、ギラン・バレー症候群(GBS)、橋本甲状腺炎、特発性血小板減少性紫斑病、若年性特発性関節炎、重症筋無力症、尋常性天疱瘡、乾癬、ライター症候群、強皮症、シェーグレン症候群、血管炎、白斑およびヴェーゲナー肉芽腫症から選択される、請求項7に記載の方法で使用するための医薬組成物。
- 前記全身性炎症性疾患が敗血症および全身性炎症反応症候群(SIRS)から選択されるか、または前記肺疾患が慢性閉塞性肺疾患(COPD)もしくは急性呼吸窮迫症候群(ARDS)、特にコロナウイルス誘発性ARDSである、請求項7に記載の方法で使用するための医薬組成物。
- 注射によって投与されるように製剤化される、請求項7~12のいずれか一項に記載の方法で使用するための医薬組成物。
- アポトーシスまたはネクロトーシスの少なくとも1つの追加の阻害剤を含む、請求項7~13のいずれか一項に記載の方法で使用するための医薬組成物。
- プリミドンまたはその薬学的に許容される活性代謝産物、誘導体、塩もしくは溶媒和物が、患者の体重1キログラム当たり1~50mgを含む量で毎日投与される、請求項7~14のいずれか一項に記載の方法で使用するための医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19196185.3A EP3789028A1 (en) | 2019-09-09 | 2019-09-09 | Primidone in the use for inhibiting cell death in diseases like reperfusion injury disease, neurodegenerative disease etc |
EP19196185.3 | 2019-09-09 | ||
EP20166882.9 | 2020-03-30 | ||
EP20166882 | 2020-03-30 | ||
PCT/EP2020/075134 WO2021048162A1 (en) | 2019-09-09 | 2020-09-09 | Compound for inhibiting cell death |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022547906A true JP2022547906A (ja) | 2022-11-16 |
Family
ID=72432923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022514837A Pending JP2022547906A (ja) | 2019-09-09 | 2020-09-09 | 細胞死を阻害する化合物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220331322A1 (ja) |
EP (1) | EP4028012A1 (ja) |
JP (1) | JP2022547906A (ja) |
WO (1) | WO2021048162A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4260858A1 (en) | 2022-04-14 | 2023-10-18 | Christian-Albrechts-Universität zu Kiel | Composition comprising primidone and peg |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002505252A (ja) * | 1997-11-20 | 2002-02-19 | ノボ ノルディスク アクティーゼルスカブ | 哺乳類細胞のアポトーシスの調整又は予防のためへのヘパリン−結合タンパク質の使用 |
-
2020
- 2020-09-09 EP EP20768593.4A patent/EP4028012A1/en not_active Withdrawn
- 2020-09-09 US US17/641,670 patent/US20220331322A1/en active Pending
- 2020-09-09 JP JP2022514837A patent/JP2022547906A/ja active Pending
- 2020-09-09 WO PCT/EP2020/075134 patent/WO2021048162A1/en active Search and Examination
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002505252A (ja) * | 1997-11-20 | 2002-02-19 | ノボ ノルディスク アクティーゼルスカブ | 哺乳類細胞のアポトーシスの調整又は予防のためへのヘパリン−結合タンパク質の使用 |
Non-Patent Citations (2)
Title |
---|
CLINICAL NEUROPHARMACOLOGY, vol. 35, no. 5, JPN6023015084, 2012, pages 224 - 226, ISSN: 0005039782 * |
EPILEPSY RESEARCH, vol. 94, no. 3, JPN6023015083, 2011, pages 138 - 148, ISSN: 0005039783 * |
Also Published As
Publication number | Publication date |
---|---|
US20220331322A1 (en) | 2022-10-20 |
EP4028012A1 (en) | 2022-07-20 |
WO2021048162A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Restelli et al. | Neuronal mitochondrial dysfunction activates the integrated stress response to induce fibroblast growth factor 21 | |
Wang et al. | Selective inhibition of the p38α MAPK–MK2 axis inhibits inflammatory cues including inflammasome priming signals | |
Xiao et al. | Neuronal-targeted TFEB accelerates lysosomal degradation of APP, reducing Aβ generation and amyloid plaque pathogenesis | |
JP6633777B2 (ja) | Glp−1組成物及びその使用 | |
JP5615805B2 (ja) | 細胞ストレス応答の調節を通したアルツハイマー病および関連障害の処置のための新たな治療アプローチ | |
TWI771269B (zh) | 胰腺炎治療 | |
Ho et al. | Pigment epithelium-derived factor is an intrinsic antifibrosis factor targeting hepatic stellate cells | |
Fernandez et al. | Blockade of the interaction of calcineurin with FOXO in astrocytes protects against amyloid-β-induced neuronal death | |
US11376229B2 (en) | Method of treating or preventing neurodegeneration | |
TW201836634A (zh) | 補體活性之調節劑 | |
EP2763688A1 (en) | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome | |
JP2008520582A (ja) | カルシウム異常により起こる状態の処置 | |
JP6548803B1 (ja) | 腎障害の抑制におけるシラスタチンの利用 | |
EP3789028A1 (en) | Primidone in the use for inhibiting cell death in diseases like reperfusion injury disease, neurodegenerative disease etc | |
JP2022547906A (ja) | 細胞死を阻害する化合物 | |
Xia et al. | Characterization and activation of NLRP3 inflammasomes in the renal medulla in mice | |
WO2016192523A1 (zh) | 阿特匹灵c及其类似物在制备防治代谢性疾病的药物中的应用 | |
Silverstein | Influence of anesthetics on Alzheimer's disease: biophysical, animal model, and clinical reports | |
Song et al. | Involvement of peripheral TRPV1 channels in the analgesic effects of thalidomide | |
US20130210143A1 (en) | Novel methods for preventing or treating diabetes | |
EP4252750A1 (en) | Pharmaceutical preservation of creb activation in the treatment of alzheimer's disease | |
WO2024099346A1 (zh) | 吲唑类化合物在治疗炎症小体激活介导的疾病中的应用 | |
US20240100069A1 (en) | Methods and Compositions for Treating Amyotrophic Lateral Sclerosis | |
WO2010104176A1 (ja) | メガリンタンパク切断阻害剤 | |
Navarro Garrido et al. | Blockade of the Interaction of Calcineurin with FOXO in Astrocytes Protects Against Amyloid-βInduced Neuronal Death |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220502 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230418 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230419 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231114 |